Drug Profile
TP 38
Alternative Names: Cervene; TP-38Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Class Antineoplastics; Drug conjugates; Immunotoxins; Proteins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 10 Jul 2006 This compound is still in active development
- 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
- 22 Nov 2004 Phase-II clinical trials in Glioblastoma in Europe (unspecified route)